Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib and Toripalimab with Radiotherapy in MSS mCRC
NCT05963490Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Apr 2023
- Primary completion
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab in colorectal cancer (metastatic) (mCRC), sponsored by Fudan University. Started Apr 2023; status: recruiting.
02
Drugs
toripalimab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT05963490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05963490.